CO2021015622A2 - Terapias de combinación que comprenden inhibidores de apremilast y tyk2 - Google Patents

Terapias de combinación que comprenden inhibidores de apremilast y tyk2

Info

Publication number
CO2021015622A2
CO2021015622A2 CONC2021/0015622A CO2021015622A CO2021015622A2 CO 2021015622 A2 CO2021015622 A2 CO 2021015622A2 CO 2021015622 A CO2021015622 A CO 2021015622A CO 2021015622 A2 CO2021015622 A2 CO 2021015622A2
Authority
CO
Colombia
Prior art keywords
apremilast
combination therapies
tyk2 inhibitors
tyk2
inhibitors
Prior art date
Application number
CONC2021/0015622A
Other languages
English (en)
Inventor
Peter Henry Schafer
Robert Plenge
Mary Adams
Lisa Beebe
Gilles Buchwalter
Tiffany Carr
Te-Chen Tzeng
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of CO2021015622A2 publication Critical patent/CO2021015622A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se proporcionan en la presente métodos para tratar enfermedades y trastornos que responden a la inhibición de PDE4 que comprende administrar apremilast y un inhibidor de Tyk2 a un sujeto. También se proporcionan en la presente composiciones farmacéuticas que comprenden apremilast y un inhibidor de Tyk2.
CONC2021/0015622A 2019-04-30 2021-11-22 Terapias de combinación que comprenden inhibidores de apremilast y tyk2 CO2021015622A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/US2019/029772 WO2020222773A1 (en) 2019-04-30 2019-04-30 Combination therapies comprising apremilast and tyk2 inhibitors
PCT/US2020/030608 WO2020223431A1 (en) 2019-04-30 2020-04-30 Combination therapies comprising apremilast and tyk2 inhibitors

Publications (1)

Publication Number Publication Date
CO2021015622A2 true CO2021015622A2 (es) 2022-02-28

Family

ID=66476870

Family Applications (2)

Application Number Title Priority Date Filing Date
CONC2021/0015614A CO2021015614A2 (es) 2019-04-30 2021-11-22 Terapias de combinación que comprenden inhibidores de apremilast y tyk2
CONC2021/0015622A CO2021015622A2 (es) 2019-04-30 2021-11-22 Terapias de combinación que comprenden inhibidores de apremilast y tyk2

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CONC2021/0015614A CO2021015614A2 (es) 2019-04-30 2021-11-22 Terapias de combinación que comprenden inhibidores de apremilast y tyk2

Country Status (14)

Country Link
EP (2) EP3962475A1 (es)
JP (2) JP2022537877A (es)
KR (2) KR20220002488A (es)
CN (2) CN114269336A (es)
AU (2) AU2019443366A1 (es)
BR (2) BR112021021809A2 (es)
CA (2) CA3138473A1 (es)
CL (1) CL2021002847A1 (es)
CO (2) CO2021015614A2 (es)
IL (2) IL287665A (es)
MA (1) MA55799A (es)
MX (2) MX2021013317A (es)
SG (2) SG11202112043PA (es)
WO (2) WO2020222773A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020222773A1 (en) * 2019-04-30 2020-11-05 Celgene Corporation Combination therapies comprising apremilast and tyk2 inhibitors
BR112023016614A2 (pt) 2021-02-19 2023-11-07 Sudo Biosciences Ltd Inibidores de tyk2 e usos dos mesmos
EP4294807A1 (en) 2021-02-19 2023-12-27 Sudo Biosciences Limited Tyk2 inhibitors and uses thereof
IL311624A (en) * 2021-09-23 2024-05-01 Bristol Myers Squibb Co Methods for treating hair loss disorders with TYK2 inhibitors
KR20240111312A (ko) 2021-10-25 2024-07-16 카이메라 쎄라퓨틱스 인코포레이티드 Tyk2 분해제 및 이의 용도

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7893101B2 (en) 2002-03-20 2011-02-22 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
US6962940B2 (en) 2002-03-20 2005-11-08 Celgene Corporation (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
GB0709031D0 (en) 2007-05-10 2007-06-20 Sareum Ltd Pharmaceutical compounds
GB0820819D0 (en) 2008-11-13 2008-12-24 Sareum Ltd Pharmaceutical compounds
TW201040162A (en) * 2009-05-06 2010-11-16 Portola Pharm Inc Inhibitors of JAK
CN103298794A (zh) 2010-11-09 2013-09-11 塞尔卓姆有限公司 作为tyk2抑制剂的吡啶化合物及其氮杂类似物
KR101889757B1 (ko) * 2011-04-28 2018-08-20 셀진 코포레이션 자가 면역 및 염증 질환의 치료 및 관리를 위한 ｐｄｅ4 저해제를 이용한 방법 및 조성물
AU2012362562B2 (en) 2011-12-27 2017-11-02 Amgen (Europe) GmbH Formulations of (+)-2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-4-acetyl aminoisoindoline-1,3-dione
KR20140108594A (ko) 2012-01-10 2014-09-11 에프. 호프만-라 로슈 아게 피리다진 아미드 화합물 및 syk 저해제로서의 이의 용도
US9187453B2 (en) 2012-03-28 2015-11-17 Takeda Pharmaceutical Company Limited Heterocyclic compound
CA2875990A1 (en) 2012-05-24 2013-11-28 Cellzome Limited Heterocyclyl pyrimidine analogues as tyk2 inhibitors
AU2013341195B2 (en) 2012-11-08 2017-09-21 Bristol-Myers Squibb Company Alkyl amide-substituted pyrimidine compounds useful in the modulation of IL-12, IL-23 and/or IFNalpha
RS63328B1 (sr) * 2012-11-08 2022-07-29 Bristol Myers Squibb Co Amidom-supstituisana heterociklična jedinjenja korisna kao modulatori il-12, il-23 i/ili ifn alfa odgovora
KR20150126618A (ko) * 2013-03-14 2015-11-12 셀진 코포레이션 아프레밀라스트를 사용하는 건선성 관절염의 치료
US20160159773A1 (en) 2013-07-30 2016-06-09 Takeda Pharmaceutical Company Limited Heterocyclic compound
CN105793245B (zh) 2013-09-03 2018-03-20 萨勒姆有限公司 药物化合物
AR094537A1 (es) 2013-11-07 2015-08-12 Bristol Myers Squibb Co COMPUESTOS DE PIRIDILO SUSTITUIDOS CON ALQUILAMIDA ÚTILES COMO MODULADORES DE LAS RESPUESTAS DE IL-12, IL-23 Y/O IFNa
JP6458038B2 (ja) 2013-12-10 2019-01-23 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ ＩＬ−１２、ＩＬ−２３および／またはＩＦＮα応答のモジュレーターとして有用なイミダゾピリダジン化合物
WO2015091584A1 (en) 2013-12-18 2015-06-25 F. Hoffmann-La Roche Ag Thiazolopyridine compounds, compositions and their use as tyk2 kinase inhibitors
US9834548B2 (en) * 2014-02-14 2017-12-05 Portola Pharmaceuticals, Inc. Pyridazine compounds as JAK inhibitors
ES2921874T3 (es) 2014-02-28 2022-09-01 Nimbus Lakshmi Inc Inhibidores de TYK2 y usos de los mismos
ES2749433T3 (es) 2014-06-23 2020-03-20 Celgene Corp Apremilast para el tratamiento de una enfermedad hepática o una anomalía de la función hepática
US10092541B2 (en) * 2014-08-15 2018-10-09 Celgene Corporation Methods for the treatment of diseases ameliorated by PDE4 inhibition using dosage titration of apremilast
NO2721710T3 (es) 2014-08-21 2018-03-31
WO2016047678A1 (ja) 2014-09-25 2016-03-31 武田薬品工業株式会社 複素環化合物
US20160251376A1 (en) 2015-02-27 2016-09-01 Nimbus Lakshmi, Inc. Tyk2 inhibitors and uses thereof
US10023571B2 (en) 2015-09-02 2018-07-17 Nimbus Lakshimi, Inc. TYK2 inhibitors and uses thereof
RS60261B1 (sr) 2016-02-24 2020-06-30 Pfizer Pirazolo[1,5-a]pirazin-4-il derivativi kao jak-inhibitori
EP3523305B1 (en) 2016-10-07 2021-12-08 Bristol-Myers Squibb Company Imidazopyridazine compounds useful as modulators of il-12, il-23 and/or ifn alpha responses
AU2017342464B2 (en) 2016-10-14 2021-09-16 Takeda Pharmaceutical Company Limited TYK2 inhibitors and uses thereof
WO2018075937A1 (en) 2016-10-21 2018-04-26 Nimbus Lakshmi, Inc. Tyk2 inhibitors and uses thereof
ES2895107T3 (es) 2016-10-28 2022-02-17 Bristol Myers Squibb Co Compuestos heterobicíclicos útiles como moduladores de las respuestas de IL-12, IL-23 y/o IFN alfa
WO2018093968A1 (en) 2016-11-17 2018-05-24 Bristol-Myers Squibb Company Imidazopyridazine modulators of il-12, il-23 and/or ifn-alpha
GB2562702B (en) 2017-03-06 2022-05-18 Linear Shaped Ltd Frame and linear shaped charge
EP4338802A3 (en) * 2017-03-08 2024-09-04 Takeda Pharmaceutical Company Limited Tyk2 inhibitors, uses, and methods for production thereof
WO2020222773A1 (en) * 2019-04-30 2020-11-05 Celgene Corporation Combination therapies comprising apremilast and tyk2 inhibitors

Also Published As

Publication number Publication date
WO2020223431A1 (en) 2020-11-05
EP3962476A1 (en) 2022-03-09
EP3962475A1 (en) 2022-03-09
BR112021021826A8 (pt) 2022-06-21
BR112021021809A2 (pt) 2022-01-04
JP2022537878A (ja) 2022-08-31
CA3138686A1 (en) 2020-11-05
IL287670A (en) 2021-12-01
CO2021015614A2 (es) 2021-12-10
WO2020222773A1 (en) 2020-11-05
SG11202112018YA (en) 2021-11-29
JP2022537877A (ja) 2022-08-31
MX2021013317A (es) 2022-01-18
CA3138473A1 (en) 2020-11-05
MX2021013318A (es) 2022-01-31
IL287665A (en) 2022-07-01
CN114269336A (zh) 2022-04-01
SG11202112043PA (en) 2021-11-29
BR112021021826A2 (pt) 2022-01-04
JP7453251B2 (ja) 2024-03-19
MA55799A (fr) 2022-03-09
CL2021002847A1 (es) 2022-07-22
KR20220002489A (ko) 2022-01-06
KR20220002488A (ko) 2022-01-06
CN114206333A (zh) 2022-03-18
AU2020266143A1 (en) 2021-12-02
AU2019443366A1 (en) 2021-12-02

Similar Documents

Publication Publication Date Title
CO2021015622A2 (es) Terapias de combinación que comprenden inhibidores de apremilast y tyk2
BR112021017495A2 (pt) Derivado de pirazina e sua aplicação na inibição de shp2
CL2021000382A1 (es) Compuestos novedosos de sulfonamidaurea
CL2020002146A1 (es) Derivados de n-(fenil)-2-(fenil)pirimidina-4-carboxamida y compuestos relacionados como inhibidores hpki para tratar el cáncer.
MX2018005600A (es) Composiciones farmaceuticas y metodos para la inhibicion de indolamina 2,3-dioxigenasa e indicaciones para ello.
BR112018001640A2 (pt) combinação de antagonista da pd-1 com um inibidor de egfr
CR20220325A (es) Fluoroalquil-oxadiazoles y sus usos
BR112015010477A2 (pt) combinação farmacêutica que compreende um inibidor b-raf e um inibidor de histona desacetilase e o uso dos mesmos no tratamento de doenças proliferativas
BR112015026021A2 (pt) terapia de combinação compreendendo um inibidor de tor quinase e n-(3-(5-flúor-2-(4-(2-met-oxietoxi)fenilamino)pirimidin-4-ilamino)fenil)acrilamida para o tratamento de câncer
BR112023015210A2 (pt) Inibidores de cdk2 e métodos de uso dos mesmos
ECSP22044525A (es) Terapia de combinaci?n que comprende un inhibidor de alk2 y un inhibidor de jak2
BR112023000687A2 (pt) Métodos e combinações de inibidores de kat6 para o tratamento de câncer
PH12021551282A1 (en) Radioimmunoconjugates and checkpoint inhibitor combination therapy
EA201790907A1 (ru) Новые производные пиразолопиримидина в качестве ингибиторов nik
EA201691555A1 (ru) Способы лечения и предотвращения заболеваний почек и жировых дистрофий печени
BR112021018739A8 (pt) Composições e métodos para o tratamento de doenças ou distúrbios associados a kras
WO2018208793A8 (en) S-NITROSOGLUTATHIOME INHIBITORS (GSNO) AND GSNO REDUCTASE USEFUL IN THERAPY
BR112022001270A2 (pt) Compostos inibidores
EA202191955A1 (ru) Таблетированные составы с модифицированным высвобождением, содержащие ингибиторы фосфодиэстеразы
MX2018008903A (es) COMPOSICIONES Y METODOS DE USO DE ß-HIDROXI-ß-METILBUTIRATO (HMB) PARA MODULAR AUTOFAGIA Y LIPOFAGIA.
CL2022001006A1 (es) Inhibidores de tim-3 y sus usos
AR116024A1 (es) Métodos de tratamiento de enfermedades neurodegenerativas
EA201990508A1 (ru) ИНГИБИРОВАНИЕ АКТИВНОСТИ Olig2
BR112022008580A2 (pt) Métodos para tratar transtornos depressivos
CL2021000282A1 (es) Inhibidores de ckd8/19